重组鼠疫汉坦钩端多抗原位点同源合成基因的表达及活性鉴定

将人工合成的含鼠疫耶尔森氏菌的2个抗原位点、汉坦病毒的5个抗原位点和钩端螺旋体的5个抗原位点的串联基因片段克隆到原核表达载体pET-20b中,构建重组表达质粒pET-rYHL.转化E.coli BL21(DE3)后获得表达菌株.表达菌株经IPTG诱导后,可高效表达带组氨酸标签的以包涵体形式存在的融合蛋白.包涵体蛋白经尿...     

重组人OCIF结构域D1～D6基因在毕赤酵母中的表达

利用PCR以实验室构建的原核重组表达质粒pProEX-OCIF为模板扩增得到N末端融合有6×His标签和rTEV蛋白酶识别序列的人破骨细胞形成抑制因子(OsteoclastogenesisInhibitoryFactor,简称OCIF)结构域D1～D6(简称O CIFm)编码基因片段;将其与pMD18-T连接,转化大肠杆菌TOP10,筛选得到阳性重组质粒pMD18-OCIFm,双酶切重组克隆质粒pMD18-OCIFm得到OCIFm基因片段;将其定向插入甲醇营养型酵母分泌表达载体pPIC9中,构建获得重组表达质粒pPIC9-OCIFm.测序验证后,以限制性内切酶SalⅠ线化,电穿孔转化酵母宿主菌GS115.筛选得到阳性表达菌株后,甲醇诱导表达4d,SDS-PAGE和Westernblot对表达情况进行分析和确认.所获得的OCIFm基因片段在甲醇营养型酵母中表达量占菌体总蛋白的30%以上.利用Ni-NTA树脂对表达产物进行一步亲和层析纯化.活性测定表明纯化的表达产物可诱导体外培养的成熟破骨细胞样细胞的凋亡.表达产物的生物学活性较利用原核表达系统明显提高.     

肠道病毒71型外壳蛋白VP2在Pichia.pastoris酵母中的表达

利用逆转录聚合酶链式反应(RT-PCR)的方法,克隆肠道病毒71型(Enterovirus 71,EV71)SHZH03株外壳蛋白VP2基因,构建酵母分泌型表达质粒pPIC9K/VP2,经序列测定证实α-factor信号肽和VP2的序列和阅读框正确后,用SacI酶切使之线性化,电转化法将目的基因整合到宿主菌GS115基因组上;经转化子表型筛选和PCR分析鉴定后,甲醇诱导筛选到高效表达VP2蛋白的工程菌株.用饱和硫酸铵法对重组蛋白VP2进行了较好的纯化.Western Blot分析表明,重组蛋白VP2具有较好的反应原性,从而为发展EV71快速、高效、廉价诊断试剂奠定了基础.     

超高效纳升液相色谱-电喷雾串联质谱鉴定重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白

采用超高效纳升液相色谱-电喷雾串联质谱对重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白进行了分析.样品经胰蛋白酶酶切后,进行液相色谱-串联质谱分析和数据库检索.结果表明, 分别有5个和7个肽段匹配于人肿瘤坏死因子受体和人Ig gamma-1 chain C region.比对分析表明,重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白中检测到的人IgG的7个肽段完全与人IgG1的序列匹配,与其它3个亚型只有部分肽段匹配.说明重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白一级结构正确,Fc片段确实为人IgG1的Fc片段.     

小鼠B7-H3-Fc融合蛋白的表达及其生物学活性的研究

目的:制备B7-H3-Fc融合蛋白,研究其对T细胞的共刺激作用.方法:首先采用PCR技术分别从pMD19-T/小鼠B7-H3和pMD19-T/hIgG1(Fc)重组载体中扩增出小鼠B7-H3胞外段基因和人IgG1重链Fc恒定区基因.通过重叠PER技术将2段基因连接成B7-H3-Fc,经EcoR I和Bgl Ⅱ双酶切后插入真核表达载体plRES2-EGFP构建成pIRES2-EG-FWB7-H3-Fc重组载体.脂质体法转染CHO细胞,经G418加压筛选能稳定分泌表达小鼠B7-H3-Fc融合蛋白的基因转染细胞,并经Western blot鉴定.该转基因细胞无血清培养后,收集细胞上清、超滤浓缩后行经Protein G柱纯化,获得纯品B7-H3-Fc融合蛋白.通过CCK-8以及ELISA方法检测小鼠B7-H3-Fc融合蛋白对T细胞体外增殖及细胞因子分泌的影响.结果:成功地构建了能稳定表达B7-H3-Fc融合蛋白基因的CHO转基因细胞株,该融合蛋白能够剂量依赖性地促进T细胞体外增殖及IL-2和IFN-γ等细胞因子分泌.结论:本研究提示B7-H3作为重要的共刺激分子,在调节T细胞免疫应答中发挥了正性共刺激作用.     

来源于Alcaligenes A-6的D-氨基酰化酶基因的合成与融合表达

将来源于Alcaligenes A-6的D-氨基酰化酶基因用大肠杆菌中的丰沛密码子替换, 利用化学和基于聚合酶链反应(PCR)技术的酶促方法进行基因全合成, 利用pET-32a构建重组表达载体pET-dan, 转化进E.coil BL21(DE3)中进行融合表达. 经SDS-PAGE电泳、 Western-blot检测和活性测定发现, D-ANase可在大肠杆菌中高效表达, 目的蛋白可达到菌体总蛋白的69.2%, 密码子优化后基因构建的工程菌发酵活性为96 U/mL, 重组蛋白经超声细胞破碎及Ni²⁺柱亲和层析纯化, 比活可达1692.3 U/mg, 纯度可达95%以上.     

亲和柱色谱原位酶切法纯化重金属镉结合的金属硫蛋白-3

按照人金属硫蛋白-3(hMT-3)的基因序列,选用大肠杆菌偏爱的密码子合成了全长hMT-3基因,并将其插入大肠杆菌融合表达质粒pALEX的多克隆位点中,在谷胱甘肽-硫-转移酶(GST)下游与GST融合表达。通过异丙基-β-D-硫代半乳糖苷(IPTG)诱导在大肠杆菌表达菌株BL21（DE3）LysS中表达了与重金属离子镉结合的融合蛋白GST-Cd2+-hMT-3。经十二烷基硫酸钠-聚丙烯酰胺凝胶电泳(SDS-PAGE)分析表明融合蛋白主要在超声上清液中。分别通过“先纯化、后酶切”和“亲和柱色谱原位酶切”两种方法纯化了Cd2+-hMT-3,比较了两种方法的纯化效率和得率,表明原位酶切法操作简便,较之“先纯化、后酶切”法减少了洗脱、透析、冻干等步骤,从而也减少了样品的损失,提高了样品的纯度和得率。从摇瓶培养菌液中纯化获得了结合有Cd2+的完整的人金属硫蛋白-3,得率为1.8%。氨基酸组成分析结果表明所获得的Cd2+-hMT-3不含芳香族氨基酸和组氨酸,符合金属硫蛋白的特征;直读电感耦合等离子体发射光谱分析其硫镉原子比为21∶(7.5±0.1),与理论值21∶7基本吻合。     

化学与酶促相结合合成并克隆核糖体失活蛋白Gelonin基因

利用已知Gelonin的氨基酸序，逆向推算出整个基因的碱基序列，根据E.coli的密码子偏爱性和后续基因克隆的需要，通过沉默突变设计相应的酶切位点和碱基序列，将整个基因分为四段，每个片段约175－220pb，每一个片段中的互补链从5′末端用化学合成100－120的碱基单链，其中两个链的3′末端有20个互补碱基。利用T4DNA聚合酶酶促添补成双链DNA，用分子克隆技术，分别构建重组子，然后再构建成含整个Gelonin基因的表达载体pET-gel进行表面，经诱导后，获得了一个28000的重组蛋白，并主要以可溶形式存在。     

人α-防御素基因克隆及其毕赤酵母表达的研究

为探讨人α-防御素(HNP2)酵母表达,根据HNP2氨基酸序列和巴斯德毕赤酵母密码偏爱性,设计HNP2基因序列片段,构建pGAPZαA-HNP2酵母表达载体,转化E.coliJM109,扩增重组子,经限制性核酸内切酶BlnI线性化,转毕赤酵母.PCR扩增挑选阳性转化子,SDS-PAGE分析酵母表达,利用阳离子交换树脂纯化HNP2,开展抗菌试验.结果显示转入巴斯德毕赤酵母HNP2基因得到表达,表达的HNP2具有显著的抗菌作用.     

猪IL-18成熟蛋白在大肠杆菌中的表达及生物学活性鉴定

以含猪IL-18全基因的重组质粒pGEM-IL-18为模板,PCR扩增猪IL-18成熟蛋白基因.将IL-18成熟蛋白片段定向插入原核表达载体pET-28a(+)中,构建重组表达质粒pET-IL-18,转化大肠杆菌BL21(DE3),在IPTG诱导下表达融合蛋白(His-IL-18),并进行融合蛋白的纯化、生物学活性鉴定.结果表明,SDS-PAGE可检测到相对分子质量约为2.1×104的融合蛋白,westem blot证实His-IL-18能与猪IL-18单克隆抗体发生特异性反应.重组猪IL-18经纯化后,能明显刺激猪脾脏T淋巴细胞增殖反应,在Marc-145细胞上抗猪繁殖与呼吸综合征病毒的活性为2.50×103IU/mg,在PK-15细胞上抗猪伪狂犬病毒、猪细小病毒的活性分别为2.00×103和2.24×103IU/mg.表明建立的表达系统能够表达重组猪IL-18,表达的重组猪IL-18具有一定的生物学活性.     

人野生型MBL基因在大肠杆菌中的表达

为获得人MBL蛋白，并对其功能进行初步研究，用DNA重组法构建了组氨到标签融合原核表达质粒pET28(b)-MBL。将重组质粒转入大肠杆菌BL21（DE3），经IPTG在37℃条件下诱导培养，利用SDS－PAGE，Westem-blot检测目的蛋白的表达，用IMAC金属螯合层析柱对其进行纯化。成功地表达了重组MBL蛋白，纯化的MBL浓度约为844μg/mL，为制备MBL的基因工程抗体奠定了基础。     

粘着斑激酶的原核表达、纯化及抗体的制备

粘着斑激酶(focal adhesion kinase,FAK)是细胞质内单亚基非受体型酪氨酸激酶,通过各种信号途径参与调节细胞生长、发育、黏附、细胞骨架重组、转化、扩散和迁移等过程.采用PCR方法,从Flag-FAK质粒中克隆编码FAK C端273个氨基酸的基因片段,构建FAK融合蛋白原核表达载体pET28a( )/FAK,进行原核表达与蛋白纯化,取纯化的FAK蛋白免疫小鼠,制备FAK抗血清.结果表明构建的表达FAK C端功能结构域的原核表达质粒pET28a( )/FAK,经过BL21(DE3)大肠杆菌表达、镍亲和层析柱纯化,获得相对分子质量约33 kDa的融合蛋白,并利用小鼠制备了多克隆抗体,EL ISA检测显示该抗体有较高效价.荧光免疫结果显示此多克隆抗体与FAK蛋白特异性结合,为进一步研究神经细胞中FAK的作用机制奠定了基础.     

Constitutive Expression of a rhIL-2-HSA Fusion Protein in Pichia pastoris Using Glucose as Carbon Source

A constitutive expression vector for rhIL-2-HSA fusion protein production in yeast Pichia pastoris was constructed. The coding gene was placed in frame with the Saccharomyces cerevisiae α-factor secretion signal sequence under the control of the GAP promoter. The recombinant plasmid pGAPZαA-rhIL-2-HSA was integrated into the genome of the P. pastoris GS115. The effect of different carbon sources on rhIL-2-HSA fusion protein expression was evaluated in shaking flask cultures. We found that recombinant P. pastoris grew well and efficiently secreted rhIL-2-HSA fusion protein into the medium when using glucose as carbon source. To achieve higher production, the influence of initial pH and culture temperature was also evaluated. Fed-batch fermentation strategy using glucose as carbon source for constitutive expression of rhIL-2-HSA fusion protein was investigated in 5-L bioreactor and the expression level of rhIL-2-HSA could reach about 250 mg/L after 60-h fermentation. The rhIL-2-HSA fusion protein produced by this constitutive expression system was purified and exhibited a specific bioactivity of 1.040?×?10⁶ IU/mg in vitro. This study described constitutive expression of rhIL-2-HSA fusion protein by P. pastoris and development of a simple high-cell density fermentation strategy for biologically active rhIL-2-HSA fusion protein using glucose as sole carbon source.     

Tandem Multimer Expression and Preparation of Hypoglycemic Peptide MC6 from <Emphasis Type="Italic">Momordica charantia</Emphasis> in <Emphasis Type="Italic">Escherichia coli</Emphasis>

Tandem repeat multimers of Momordica charantia (MC) peptide MC6 were designed and the recombinant plasmid containing 10 copies of MC6 gene was constructed to improve the expression level of MC6 in Escherichia coli. Under the selected conditions of cultivation and induction, the expression level of recombinant TrxA–MC6₁₀ protein was above 25% of total bacteria protein. This fusion protein was purified and cleaved with HCl (13%, w/v). Either the un-cleaved or cleaved recombinant proteins was analyzed pharmacological activity by alloxan-induced diabetic mice and only the cleaved products of the recombinant protein showed significant hypoglycemic effects. The study provides a convenient and economical method for the large-scale production of anti-diabetic medicines for pharmaceutical applications.     

Construction and Expression of Human Survivin and Preparation of Its Polyclonal Antibody

Survivin, a novel member of inhibitor of apoptosis（IAP） protein family, is aberrantly expressed in cancer but undetectable in normal, differentiated adult tissues. The cancer-specific expression of survivin, coupled with its importance in inhibiting cell death and in regulating cell division makes it a useful diagnostic marker of cancer and a potential target for cancer treatment. Survivin cDNA amplified from the total RNA of 293 cells through RT-PCR was cloned into prokaryotic expression vector pRSET-B. The recombinant plasmid pRSET-B-Surv was expressed in E.coli BL21, and the relative molecule mass（Mr） of expressed fusion protein was approximately 21000. The recombinant protein was purified through Ni^2＋ affinity chromatography column and characterized by SDS-PAGE and Western blot. The purified recombinant protein was then injected into rabbits, and antisurvivin polyclonal antibody with a high titer was obtained.     

Cloned s-Lap Gene Coding Area, Expression and Localization of s-Lap／GFP Fusion Protein in Mammal Cells

s-Lap is a new gene sequence from pig retinal pigment epithelial (RPE) cells, which was found and cloned in the early period of apoptosis of RPE cells damaged with visible light. We cloned the coding area sequence of the novel gene of s-Lap and constructed its recombinant eukaryotic plasmid pcDNA3.1-GFP/s-lap with the recombinant DNA technique. The expression and localization of s-lap/GFP fusion protein in CHO and B16 cell lines were studied with the instantaneously transfected pcDNA3.1-GFP/s-lap recombinant plasmid. s-Lap/GFP fusion protein can be expressed in CHO and B16 cells with a high rate expression in the nuclei.     

Feasibility of a recombinant human apolipoprotein E reference material

The aim of this work was to prepare a recombinant apo E material and to determine its suitability as a reference material. We produced human apo E3 using recombinant DNA technology. The cDNA of human apo E3 was cloned in the pARHS bacterial expression vector and used to transfect E. Coli BL21 (DE3) cells. The recombinant protein was then purified in one step by affinity chromatography on a Ni-chelated agarose column under denaturing conditions. The purity of the protein estimated by SDS PAGE was greater than 96%. The physicochemical properties and biological and immunological reactivity of the purified recombinant apo E3 were shown to be close to those of the protein purified from human plasma VLDL. A limited batch of lyophilized apo E material was then prepared. The stability of the lyophilized apo E material examined by temperature accelerated degradation was acceptable. No degradation of the measured apo E was observed after storage of the lyophilized material at +4°?C and –20°?C for 11 months. The reconstituted lyophilized material, in comparison with human fresh serum samples and with apo E purified from human VLDL, showed no major alteration of its immunological reactivity when assayed by immunoturbidimetry or ELISA.     

Topological characterisation and identification of critical domains within glucosyltransferase IV (GtrIV) of Shigella flexneri

Background

Uncharacterized proteases naturally expressed by bacterial pathogens represents important topic in infectious disease research, because these enzymes may have critical roles in pathogenicity and cell physiology. It has been observed that cloning, expression and purification of proteases often fail due to their catalytic functions which, in turn, cause toxicity in the E. coli heterologous host.

Results

In order to address this problem systematically, a modified pipeline of our high-throughput protein expression and purification platform was developed. This included the use of a specific E. coli strain, BL21(DE3) pLysS to tightly control the expression of recombinant proteins and various expression vectors encoding fusion proteins to enhance recombinant protein solubility. Proteases fused to large fusion protein domains, maltosebinding protein (MBP), SP-MBP which contains signal peptide at the N-terminus of MBP, disulfide oxidoreductase (DsbA) and Glutathione S-transferase (GST) improved expression and solubility of proteases. Overall, 86.1% of selected protease genes including hypothetical proteins were expressed and purified using a combination of five different expression vectors. To detect novel proteolytic activities, zymography and fluorescence-based assays were performed and the protease activities of more than 46% of purified proteases and 40% of hypothetical proteins that were predicted to be proteases were confirmed.

Conclusions

Multiple expression vectors, employing distinct fusion tags in a high throughput pipeline increased overall success rates in expression, solubility and purification of proteases. The combinatorial functional analysis of the purified proteases using fluorescence assays and zymography confirmed their function.